Regeneron Pharmaceuticals Inc. (REGN)
$635.45
$6.72
(1.07%)
As on 05-Jun-2026 16:00EDT
Market cap
$64,453 Mln
Revenue (TTM)
$14,920 Mln
P/E Ratio
15
P/B Ratio
2.1
Div. Yield
0.6 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
13.6 %
-
Industry P/E
--
-
EV/EBITDA
10.4
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$41
-
Face value
--
-
Shares outstanding
103,021,886
10 Years Aggregate
CFO
$28,809.62 Mln
EBITDA
$33,451.99 Mln
Net Profit
$27,518.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| -17.7 | -10.4 | -19.3 | 31.0 | -4.9 | 4.4 | 4.7 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| 8.4 | -18.8 | 21.9 | 14.2 | 30.7 | 28.7 | 0.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
|
635.5 | 64,452.9 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15 | 2.1 |
| 303.1 | 40,318.1 | 4,286.9 | 577.2 | 9.8 | 88.2 | 75.7 | 36.7 | |
| 94.2 | 23,173.0 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 33.5 | |
| 74.5 | 12,642.6 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.7 | |
| 183.5 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 47.4 | 18,724.3 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.6 | |
| 163.9 | 15,917.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 24.3 | 4.7 | |
| 14.8 | 13,613.9 | 0.0 | -872.2 | -- | -287.7 | -- | 24.7 | |
| 549.9 | 23,635.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.6 | 4.0 | |
| 446.8 | 113,588.1 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic,... neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York. Read more
-
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
-
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
-
Headquarters
Tarrytown, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Regeneron Pharmaceuticals (REGN)
What is the current share price of Regeneron Pharmaceuticals Inc (REGN) Today?
The share price of Regeneron Pharmaceuticals Inc (REGN) is $635.45 (NASDAQ) as of 05-Jun-2026 16:00 EDT. Regeneron Pharmaceuticals Inc (REGN) has given a return of -4.95% in the last 3 years.
What is the current PB & PE ratio of Regeneron Pharmaceuticals Inc (REGN)?
The P/E ratio of Regeneron Pharmaceuticals Inc (REGN) is 15.02 times as on 29-May-2026.
The P/B ratio of Regeneron Pharmaceuticals Inc (REGN) is 2.09 times as on 29-May-2026, a 53 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.42
|
2.65
|
|
2024
|
18.37
|
2.76
|
|
2023
|
25.31
|
3.85
|
|
2022
|
18.96
|
3.63
|
|
2021
|
8.85
|
3.81
|
What is the 52 Week High and Low of Regeneron Pharmaceuticals Inc (REGN)?
The 52-week high and low of Regeneron Pharmaceuticals Inc (REGN) are Rs 821.11 and Rs 476.49 as of 07-Jun-2026.
What is the market cap of Regeneron Pharmaceuticals Inc (REGN)?
Regeneron Pharmaceuticals Inc (REGN) has a market capitalisation of $ 64,453 Mln as on 29-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Regeneron Pharmaceuticals Inc (REGN)?
Before investing in Regeneron Pharmaceuticals Inc (REGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.